Oral FGFR3 kinase inhibitors for achondroplasia — the small molecule therapies directly blocking the constitutively active mutant FGFR3 receptor at the tyrosine kinase domain, offering pill-based disease modification without daily injections — represent the fastest-advancing pipeline category in the global skeletal dysplasia landscape, with the Achondroplasia Market reflecting oral...